glp-1 and eating disorder Experts express alarm that RAs may trigger or worsen disorders. But is there any role they might play in binge eating disorder? how can clinicians protect patients from risk? They Used GLP-1s to Lose

Still, insurance coverage and cost considerations mean both drugs remain relevant, and patient-centred conversations about therapy choice are critical. GLP-1s beyond weight loss as multi-system therapies Liver disease and metabolic steatohepatitis Non-alcoholic fatty liver disease (NAFLD) and the more severe metabolic dysfunction-associated steatohepatitis (MASH) have few effective pharmacologic treatments

It works by activating an enzyme in your cells called AMPK, which plays a key role in helping regulate metabolism19 and energy levels

Haiman CA, Hankinson SE, Vivo ID, Guillemette C, Ishibe N, Hunter DJ et al

At 12 weeks (roughly 3 months), average weight loss with semaglutide 2.4mg is approximately 6 to 8% of starting body weight